Opmind Secures Tens of Millions RMB Strategic Financing Led by Cinda Kunpeng, with HaoYue Capital as Exclusive Financial Advisor

VCBeat has learned that Guangdong OptoMedic Technologies, Inc. recently completed a strategic financing round worth tens of millions of yuan, led by Xinda Kunpeng (Shenzhen) Equity Investment Management Co., Ltd., with HAOYUE CAPITAL serving as the exclusive financial advisor across multiple rounds.

OptoMedic, founded in 2013, is a globally leading platform-based innovative enterprise in the endoscopy field, specializing in the research, development, and manufacturing of high-end medical devices.Comprehensive full-featured endoscopic imaging platform, fluorescence laparoscopy series, white-light laparoscopy series, flexible electronic endoscopy series, single-use endoscope series, fluorescence contrast agents, energy-based device consumables, and other products, continuously expanding in the field of minimally invasive surgery. Over the past decade, OptoMedic has remained committed to technological innovation and original foundational research, taking the lead in breaking the import monopoly on high-end endoscopes.

This financing round, which swiftly followed the completion of the company’s Pre-IPO round in June, marks the strategic introduction of Xinda Kunpeng, which will continue to support the expansion of the company’s overseas business and the further integration and optimization of its supply chain system.

Leveraging years of sustained dedication and exploration in the field of high-end medical endoscopy, OptoMedic has established significant scale advantages. The company has built a vertically integrated supply chain system that connects raw materials, production, R&D, warehousing, and logistics with its global sales network. This system achieves a high degree of vertical integration across the entire value chain, from upstream key components and midstream complete equipment manufacturing to downstream product branding.

Currently,OptoMedic has established three major production bases in China, further achieving full in-house research, development, and manufacturing of multiple components., keeping resources such as the production of core technologies and key components in-house to further ensure the stability and flexibility of the supply chain.

OptoMedic is actively expanding its overseas market and has obtained multiple certifications, including FDA and CE approvals. It has also completed MDR certification for certain products following the reform of the EU registration system, with several more products scheduled for launch in 2024. Currently,OptoMedic’s products have successfully entered markets in Germany, Italy, and other countries, gradually building the brand’s global influence. Meanwhile, OptoMedic is intensifying its overseas patent layout and accelerating international registration and certification to expedite the global deployment of its products., expand global market promotion and layout, and continuously improve the construction of the global marketing and service ecosystem platform.

To further expand its international market presence, OptoMedic has frequently showcased its new products and technologies at prestigious international exhibitions. In 2023, OptoMedic’s teams participated in trade shows in Germany, Italy, the United States, South Korea, and other countries, securing numerous prospective clients. At MEDICA 2023 (the International Hospital and Medical Equipment Exhibition) in Düsseldorf, Germany, OptoMedic exhibited products such as the Stellar 4K 3D Fluorescence Endoscopy Imaging Platform and the 4K Ultra-High-Definition Fluorescence Navigation Endoscopy System. These innovations received high acclaim from experts, who unanimously agreed that they offered an excellent user experience in terms of clarity, depth perception, and comfort, demonstrating significant clinical value. Meanwhile, OptoMedic has collaborated with research institutions and universities to conduct high-level research on key core endoscopic technologies at the international forefront. Its leading advancements in semi-quantitative analysis and 3D reconstruction have attracted considerable attention from the global market.

Dr. Xin An, Founder of the CompanyOptoMedic stated that it has broken through market barriers by leveraging its fluorescence endoscopy technology and is continuously launching innovative endoscopic products at a pace of biennial updates, ensuring each new release maintains a leading edge. The company is also advancing the in-house research, development, and manufacturing of core components, striving to overcome critical technological bottlenecks and achieve mastery over key technologies. We extend our gratitude to both existing and new shareholders for their support; we will proceed with greater stability and confidence step by step.

Zhao Yanchen, Executive Deputy General Manager of Xinda Kunpeng“It is stated that in today’s era of widespread adoption of minimally invasive surgery, endoscopes are among the most critical surgical tools for physicians. Due to the long-standing monopoly by German and Japanese enterprises, endoscopy remains one of the medical device sectors with the lowest rate of domestic production in China. We are optimistic about the growth prospects of the endoscopy sector amid the trend toward precision and minimally invasive procedures. We are also pleased to see that OptoMedic, as a leading player in this field, has accumulated substantial technological expertise and successfully achieved commercialization. Through our participation in this round of financing, we aim to support the company’s strategic mergers and acquisitions and integrated development, thereby facilitating its continued breakthroughs in the global market.”

Mr. Yang Zhenjun, Managing Partner of HAOYUE CAPITAL“We are honored to have assisted the company in completing this financing round this year. During the critical period of 2022 and 2023, when the primary healthcare market in China experienced a significant downturn, we have consistently remained bullish on companies like OptoMedic that boast a multidisciplinary team, profound technological expertise, and a platform-based product portfolio. We wish OptoMedic continued success and growth! We will continue to stand by the team, helping them navigate market cycles and thrive against the headwinds.”